Ulcerative Colitis
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
VIDEO: Risankizumab bests placebo at 52 weeks in UC, regardless of induction outcomes
PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.
‘No meaningful difference’: Zymfentra monotherapy as effective as combined therapy for IBD
PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.
VIDEO: Primary sclerosing cholangitis increases risk for CRC, even among those without IBD
PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.
FDA expands approval of Stelara biosimilar Selarsdi to include UC, Crohn’s disease
The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.
Researchers identify genetic biomarker linked to risk for severe ulcerative colitis
The human leukocyte antigen DRB1*01:03 allele was associated with severe ulcerative colitis, along with greater odds for major operation, hospitalization and corticosteroid use, according to results of a Danish study.
Imuldosa snags FDA approval as fifth Stelara biosimilar in mounting market logjam
The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.
JAK inhibitors: ‘A valuable addition’ to the IBD treatment portfolio
This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.
‘Don’t shy away’ from JAKs in IBD: Monitor patient outcomes, understand potential risks
Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.
FDA approves Otulfi as fourth Stelara biosimilar for chronic inflammatory diseases
The FDA has approved subcutaneous and IV formulations of the Stelara biosimilar Otulfi for Crohn’s disease, ulcerative colitis and all other indications approved for the reference product, according to a press release from Fresenius Kabi.